The Global Rapid Diagnostic Tests (RDT) Market is expected to grow with a CAGR of 9.3% in the forecast period of 2022 to 2029. The years considered for the study are as mentioned below.

Access Full Report @ https://www.databridgemarketresearch.com/reports/global-rapid-diagnostic-tests-rdt-market

The global rapid diagnostic tests (RDT) market is a highly consolidated market, which includes a specific number of key players. The market has witnessed increased strategic developments owing to favorable market scenarios.

The major players dealing in the global rapid diagnostic tests (RDT) market are introducing a strong range of product providers, launching new products, and adopting strategic initiatives such as acquisition, agreement, business expansion, award, and recognition. This helped companies to maximize sales with an enhanced product portfolio.

For instance,

• In October 2020, Siemens Healthcare GmbH had launched the rapid COVID-19 antigen test to detect the SARS-COV-2. This product launch ensured the distribution of kits to healthcare professionals

Abbott is expected to dominate the global rapid diagnostic tests (RDT) market. The other key players existing in the market are Danaher, Cellex, AdvaCare Pharma, Access Bio, Cardinal Health, Bio-Rad Laboratories, Inc., BD, F. Hoffmann-La Roche Ltd, bioMérieux SA, InBios International, Inc., Gnomegen LLC, QIAGEN, Quidel Corporation, Chembio Diagnostics Systems, Inc., Siemens Healthcare Gmbh (A Subsidiary Siemens Healthineers AG), PerkinElmer Inc., Sekisui Diagnostics, Fujirebio (A Subsidiary of H.U. Group), PTS Diagnostics, LamdaGen Corporation, Werfen, Nova Biomedical, Trinity Biotech, Sysmex Europe GmbH (A Subsidiary of Sysmex Corporation), Luminex Corporation. A DiaSorin Company, MEGAKOR DIAGNOSTK GMBH, among others.

Abbott

Abbott was founded in the year 1888 and has headquarters in Illinois, U.S. It has public ownership. The company focuses on the manufacturing of devices to manage chronic pain, and diabetes, among others. The company operates its business via several business segments established pharmaceutical products, nutritionals, diagnostics, medical devices, other, in which diagnostics is the market-focused segment.

The company provides products via various product categories such as cardiovascular, diabetes care, diagnostics, neuromodulation, nutrition and medicines, in which diagnostics is the market-focused category.

For instance,

• In June 2019, Abbott launched the AfinionHbA1c Dx assay with Afinion 2 Analyzer to provide a quick point of care test for patients who have diabetes. This device uses a capillary blood sample to deliver accurate glycated hemoglobin results in only three minutes. This product launch helped the company enhance its capillary blood collective device platform and generate more revenue by-product sales

The company has a wide presence across the Americas, Europe, Asia-Pacific and the Middle East and Africa. The company also has various subsidiary companies such as Abbott Cardiovascular Systems Inc. (U.S.), Abbott Nutrition Manufacturing Inc. (U.S.), Abbott Laboratories Pacific Ltd.(U.S.), Abbott Resources Inc. (U.S.), and PDD II, LLC (U.S.), among others.

F. Hoffmann La-Roche Ltd

F. Hoffmann-La Roche Ltd was founded in 1896, headquartered in Basel, Switzerland. It has public ownership. The company is engaged in creating innovative medicines and diagnostics tests that help millions of people worldwide. The company operates its business via several business segments, including pharmaceuticals, diagnostics in which diagnostics is the market-focused segment.

The company provide products via various product categories such as Clinical Chemistry & Immunoassays, Molecular Diagnostics, Tissue Diagnostics, Point Of Care Diagnostics, Laboratory Automation & IT, Haematology & Haemostasis, Urinalysis, Patient Self-testing, Solutions For Life Science, Custombiotech Solution in which Molecular Diagnostics is the market-focused category.

For instance,

• In January 2018, F. Hoffmann-La Roche Ltd launched Cobas Plasma, Separation Card. This new solution is a stable and easy-to-use sample collection device for HIV plasma viral load testing. This raises the company’s sales and product portfolio

The company has a presence across North America, Europe, Africa, Asia and Oceania. The company also has various subsidiaries, including Roche Diagnostica Brasil Ltda. (Brazil), Roche Diabetes Care Brasil Ltda. (Brazil), Trophos SA (France), INSTITUT ROCHE SAS (France), and Roche Diagnostics K.K. (Japan), among others.

Siemens Healthcare GmbH

Siemens Healthcare GmbH was incorporated in the year 1896, headquartered in Forchheim, Germany. It has public ownership. The company provides laboratory diagnostics, medical imaging, digital ecosystem, and reading solutions, among others. The company operates its business via several business segments, including imaging, diagnostics & advanced therapies, in which diagnostics is the market-focused segment.

The company provides products via various product categories such as Medical Imaging, Laboratory Diagnostics, Point of Care Testing, Digital Health Solutions, Services & Consulting, Clinical Specialties, Accessories, OEM & Electronics & Healthcare IT, in which Point of Care Testing is the market-focused category.

For instance,

• In April 2021, Siemens Healthcare GmbH launched the Atellica VTLi Patient-Side Immunoassay Analyzer, which had obtained the CE mark for the diagnosis of a heart attack. The Atellica VTLi analyzer provides high-sensitivity cardiac troponin I test results to clinicians in eight minutes. The product launch would result in a rise in demand for the analyzer by clinicians and would result in product expansion of the Atellica VTLi Patient-Side Immunoassay Analyzer in North America and Europe

The company has a presence across North America, Europe and Asia. The company has various subsidiaries such as Fast Track Diagnostics Ltd. (Europe), Siemens Healthcare Medical Solutions Limited (Germany), Siemens Healthcare Germany (Germany), among others.